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Abstract  
White adipose tissue (WAT) is an endocrine and lipid storage organ that is imperative to mammals 
for the maintenance of energy homeostasis. WAT depot size and triacylglycerol (TAG) content is 
determined by the regulation of lipid metabolism in adipocytes, as well as by the number of 
adipocytes. The two main processes in TAG metabolism are hydrolysis (or lipolysis), and synthesis, 
which encompasses both de novo fatty acid synthesis, and complex lipid synthesis via the Kennedy 
pathway. The number of adipocytes is regulated primarily by adipogenesis, the differentiation of 
preadipocytes into fully mature adipocytes. Dysregulation of adipocyte lipid metabolism or 
adipogenesis can lead to pathological conditions such as obesity, diabetes, and cardiovascular 
disease. Thus, the maintenance of a healthy physiological state is critically dependent on normal 
adipose tissue development and function. The 1-acylglycerol-3-phosphate-O-acyltransferases 
(AGPATs) catalyze the second step in the Kennedy pathway, acylating lysophosphatidic acid (LPA) 
with a fatty acyl-CoA at the sn-2 position, forming phosphatidic acid (PA). LPA and PA are 
bioactive signalling molecules that may affect the differentiation of adipocytes, while PA is also a 
building block for the synthesis of TAG and phospholipids that are components of expanding 
adipocytes. Changes in the activity of cellular AGPATs may therefore affect adipose tissue biology 
through multiple mechanisms. Little is known however, about the role of most of the AGPAT 
homologues in WAT. In this study, we aimed to better understand the in vivo function of AGPAT 
homologue 4 (AGPAT4) in WAT by using a gene ablation model of Agpat4 to assess the role of this 
enzyme in three important white adipose tissue regulatory processes: lipogenesis, adipogenesis, and 
lipolysis. It was hypothesized that lack of AGPAT4 would reduce TAG synthesis, resulting in 
decreased whole body weights due to reductions in individual adipose tissue depot masses. Since 
TAG synthesis is required for adipocyte differentiation, it was further hypothesized that loss of 
AGPAT4 would impair differentiation. We predicted a compensatory reduction in adipocyte lipolysis 
would also be observed. Contrary to these predictions, it was found that AGPAT4 ablation resulted in 
a 40% increase in the mass of epididymal WAT, without causing a significant change in whole body 
weights, food intake, activity, oxygen consumption, or substrate oxidation. This was accompanied by 
a 26% increase in TAG content in epididymal WAT and an increase in the average adipocyte size 
within this depot, with no observed changes in the gene expression of adipogenic markers. The 
expression of genes encoding LIPIN1 and DGAT1 showed significant upregulation in epididymal 
WAT however, there were no changes in gene expression or protein content of other markers of 
lipogenesis. Agpat4-/- epididymal WAT showed a decrease in ATGL, P-HSL S563, and P-HSLS660 
content, decreased total triolein lipase activity, and dibutyryl-cAMP stimulated glycerol release, 
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indicating a decrease in lipolytic activity. In contrast, no differences in any measures of lipogenesis, 
lipolysis, or adipogenesis were observed for perirenal WAT with the exception of a compensatory 
upregulation of the other AGPAT isoforms. Notably, this compensation was not observed in 
epididymal WAT, which paradoxically exhibited an increase in PA content. Our findings suggest that 
induction of the other AGPAT isoforms may be responsible for maintaining normal adipocyte 
differentiation and function in perirenal WAT, but that this compensation does not occur in 
epididymal WAT, which consequently becomes dysregulated.   
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Chapter 1: Introduction 
 
 White adipose tissue (WAT) is an endocrine organ that is imperative to mammals for the 
maintenance of energy homeostasis. It is a form of loose connective tissue composed of specialized 
cells, known as adipocytes, as well as nerve tissue, stromovascular cells, and immune cells (1). 
Together, these components form an integrative unit that acts as an energy reserve, as thermal 
insulation, and as an endocrine organ involved in adipokine signaling throughout the body (2, 3). 
WAT is distributed throughout the body in several regional depots that have known differences in 
size, organization, and biological function. The main depots include visceral WAT, the adipose tissue 
surrounding inner organs in the thoracic and abdominal cavities, as well as subcutaneous WAT, the 
adipose tissue directly beneath the skin, which have been shown to have different developmental 
origins (2, 4).  
During a positive energy state, or energy excess, WAT stores energy in the form of 
triacylglycerol (TAG), which is composed of three fatty acyl chains esterified to a glycerol backbone. 
During a negative energy state, or energy deprivation, WAT hydrolyzes TAG, in a process termed 
lipolysis, to liberate glycerol and free fatty acids that can be used by other organs as energy 
substrates (5). WAT size and TAG content is determined by the regulation of lipid metabolism in 
adipocytes, including lipid synthesis and lipolysis, as well as adipogenesis, the process in which 
adipocytes differentiate into fully mature adipocytes from precursor preadipocytes. Dysregulation of 
any one of these processes can lead to detrimental disorders (1). In particular, obesity, which is 
caused by excess WAT, and is rising in prevalence, is associated with metabolic disorders, such as 
type II diabetes and dyslipidemia, hypertension, atherosclerosis, and cardiovascular disease (6).  
An increase in WAT, or fat mass, requires an increase in adipocyte size (hypertrophy) or an 
increase in adipocyte number (hyperplasia) (7). At least in the early stages, obesity primarily results 
from adipocyte hypertrophy rather than hyperplasia, and is caused when TAG synthesis exceeds 
TAG breakdown (7). Unlike most other cell types in the body, adipocytes are well suited to the 
storage of TAG and the expansion of adipocyte TAG stores is not immediately detrimental to health, 
per se. Rather, pathological conditions primarily ensue when the hypertrophic expansion of 
adipocytes results in hypoxia, fibrosis, and inflammation within the tissue, which can then cause 
insulin resistance (8, 9). These conditions are observed more frequently in hypertrophic visceral 
WAT depots and less often in subcutaneous WAT depots (10). As a result, visceral WAT mass tends 
to correlate with the development of insulin resistance, whereas total adipose tissue depot size, and 
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the size of subcutaneous adipose tissue, does not (5, 10). This has been attributed to multiple factors 
such as differing degrees of inflammation, levels of adipokines, and response to insulin-sensitizing 
compounds such as thiazolidinediones (TZDs). The higher metabolic activity of visceral WAT has 
also been suggested as a factor linking this depot to the development of pathological conditions in 
obesity. Visceral WAT has been shown to have greater mitochondrial content, higher rates of 
oxidative phosphorylation, higher rates of lipolysis, as well as higher insulin-stimulated glucose 
uptake per weight of fat mass (10-13). Therefore, visceral WAT may contribute more to the levels of 
plasma free fatty acids than subcutaneous WAT, as well as enhanced free fatty acid delivery to the 
liver, resulting in increased very low density lipoprotein (VLDL) output and impaired hepatic insulin 
response (10). It has therefore been suggested that subcutaneous WAT may provide a greater and 
more metabolically beneficial storage capacity for TAG (10). Within both subcutaneous and visceral 
WAT however, are several distinct depots anatomically separated from one another. For example, 
visceral WAT is composed of six depots: gonadal/epididymal, perirenal, epicardial, retroperitoneal, 
omental, and mesenteric, and little is known about their individual biochemical properties (4).  
Expansion of WAT through hyperplasia, resulting from increased adipogenesis, tends to 
occur with ascending obesity. It has been suggested that hyperplasia may follow hypertrophy in 
adipocytes once they have reached a maximum size, or critical volume (2). Hyperplasia therefore, 
may provide an adaptive and protective role to maintain insulin sensitivity (9). Indeed, increased 
adipocyte differentiation is a component of the insulin sensitizing action of some pharmaceutical 
agents, such as TZDs (14, 15). Conversely, lipodystrophy, which is characterized by a lack of WAT 
due to impaired TAG biosynthesis, accelerated TAG hydrolysis, or inadequate adipogenesis, is 
associated with insulin resistance, diabetes, and subsequent metabolic complications (16, 17). Thus, 
proper development, regulation, and maintenance of WAT cell number and TAG content is necessary 
for metabolic health, and understanding the factors underlying these processes may help provide 
treatment options for metabolic disease. It is therefore imperative to understand the biochemical 
pathways and enzymatic regulation of TAG. The acylglycerophosphate acyltransferase (AGPAT) 
group of enzymes function in the second step of the Kennedy pathway for the de novo synthesis of 
glycerolipids and TAG. The AGPAT isoforms show differential tissue distribution, but the 
physiological significance of this distribution, and the role of each isoform in different tissues 
including WAT, is not well understood (18). AGPAT isoform 4 (AGPAT4) shows evidence of 
expression in WAT, but its biochemical properties and physiological importance in this tissue have 
yet to be investigated.  
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Chapter 2: Biochemical Foundations 
 
Lipolysis 
Lipolysis is the sequential hydrolysis of TAG via the action of lipases, resulting in the release 
of a fatty acid at each step. Adipose-triglyceride lipase (ATGL) is the major enzyme involved in the 
hydrolysis of TAG (5). It is located both in the cytoplasm and on the lipid droplet where it 
preferentially cleaves a fatty acyl chain from the sn-2 position of TAG, forming diacylglycerol 
(DAG) (19). Hormone-sensitive lipase (HSL) subsequently cleaves a fatty acyl chain from the sn-1 
or sn-3 position of DAG (19). Similar to ATGL, HSL is also a cytoplasmic lipase, but it translocates 
to the lipid droplet when activated by the phosphorylation of protein kinase A (PKA) (20). 
Hydrolysis of DAG results in the formation of monoacylglycerol (MAG) that is hydrolyzed by 
monoglyceride lipase (MGL) in the cytosol to liberate glycerol and the final fatty acyl chain (5).  
 This process is regulated under hormonal control where, in times of energy excess, insulin 
acts to inhibit lipolysis, and in times of energy deprivation, catecholamines and glucocorticoids act to 
stimulate it (21).  Catecholmines activate Ga-coupled receptors which stimulate adenylate cyclase, 
resulting in increased intracellular cyclic adenosine monophosphate (cAMP) concentrations. 
Increased cAMP levels activate cAMP-dependent PKA resulting in the phosphorylation of HSL at 
serine residues 563, 659, and 600, and increased hydrolytic activity at the lipid droplet (21). HSL 
may also be phosphorylated at serine site 565 by 5’adenosine monophosphate-activated protein 
kinase (AMPK), a cellular energy sensor (5, 21, 22). The action of HSL is also mediated by the lipid 
droplet-associated protein, perilipin A. When phosphorylated by the action of PKA, perilipin A has 
been shown to result in increased activity of HSL, perhaps through facilitation of HSL translocation 
to the lipid droplet, although findings have been variable (5, 23, 24). Glucocorticoids have been 
shown to induce ATGL expression. However, ATGL activity does not appear to be mediated by 
PKA or by translocation, since it is localized to the lipid droplet under both basal and hormonally 
stimulated conditions (21). AMPK has been shown to phosphorylate and activate ATGL, thereby 
stimulating lipolysis (22, 25). 
 
Adipogenesis 
Adipogenesis describes the development of an undifferentiated mesenchymal cell into a 
preadipocyte, which undergoes changes in morphology and gene expression to become a mature, 
lipid filled, insulin-responsive adipocyte (17). Adipocyte differentiation occurs during embryonic 
development, and although TAG storage in adipocytes largely results in increased adipocyte size, it 
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may also result in increased adipocyte differentiation (2). Adipogenesis is regulated by various 
classes of transcription factors which include sterol response element-binding proteins (SREBPs), the 
peroxisome proliferator-activated receptor (PPAR) family proteins, CCAAT/enhancer-binding 
proteins (C/EBPs), and signal transducers and activators of transcription (STATs) (17). Two of the 
transcription factors most commonly analyzed when assessing adipocyte differentiation are C/EBPa 
and PPARγ, since these nuclear factors are central to adipogenesis. Preadipocyte factor 1 (PREF-1) is 
an anti-adipogenic protein that directly regulates C/EBPb and C/EBPd (17). C/EBPb and C/EBPd 
target the promoters of genes for SREBP1, C/EBPa, as well as PPARγ, which subsequently form a 
heterodimer with the retinoid X receptor and bind to the DNA of various genes involved in 
adipogenesis. These include C/EBPa (which creates a positive feedback loop), aP2/FABP4 
(adipocyte protein 2/fatty acid binding protein 4), ADIPOQ (Adiponectin, C1Q And Collagen 
Domain Containing), fatty acid synthase (FAS), perilipin, and AGPAT2 (17, 26).  
 
The Kennedy pathway of complex glycerolipid synthesis 
 Glycerolipid synthesis occurs in the Kennedy pathway, which was first described by Eugene 
Kennedy in 1956 (27). The enzymes in this pathway regulate the production of TAG and the 
phospholipids phosphatidic acid (PA), phosphatidylcholine (PC), phosphaditylethanolamine (PE), 
phosphatidylglycerol (PG), phosphatidylinositol (PI), and cardiolipin (CL), and also influence the 
unique fatty acid composition of these lipid species (Fig. 1) (27, 28). The Kennedy pathway begins 
with the formation of glycerol-3-phosphate (G3P), an intermediate derived from the glycolysis 
pathway, since most extra-hepatic tissues lack significant glycerol kinase activity and therefore, 
cannot directly activate (or reactivate) glycerol. The first committal step of the Kennedy pathway is 
the acylation of G3P to produce 1-acylglycerol-3-phosphate, also known as lysophosphatidic acid 
(LPA). This is achieved by one of the four members of the glycerophosphate acyltransferase (GPAT) 
family that transfer a fatty acyl-coenzyme A (CoA) to the sn-1 position of G3P. GPATs have the 
lowest specificity for enzymatic activity of all the enzymes involved in the Kennedy pathway (29). 
These enzymes catalyze both the initial and the rate limiting step in glycerolipid synthesis (29). 
Following the acylation of G3P, a fatty acid is transferred from an acyl-CoA to the sn-2 position of 
the glycerol backbone of LPA to produce PA. This reaction is catalyzed by a member of the 1-
acylglycerol-3-phosphate-O-acyltransferase (AGPAT) family, also known as a lysophosphatidic acid 
acyltransferase (LPAAT) (30). PA is an important branching point in the Kennedy pathway since it 
acts as the precursor to all membrane glycerophospholipids and TAG in mammals. PA can be 
shunted into one of two pathways. One pathway begins with the production of cytidine diphosphate-
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diacylglycerol (CDP-DAG) ultimately leading to the production of PI, PG, or CL (27). The 
alternative pathway begins with the production of DAG and ultimately leads to the production of PC, 
PE, PS, or to the production of TAG (31).  
 
 The pathway leading to the production of PI, PG, and CL begins with the condensation of 
cytidine triphosphate (CTP) with PA, as catalyzed by CDP-DAG synthase (CDS), also known as 
phosphatidate cytidylyltransferase, to produce CDP-DAG. CDG-DAG can react with inositol to 
produce PI, as catalyzed by phosphatidylinositol synthase (PIS), which is also known as CDP-DAG 
inositol 3-phosphatidyltransferase (32). CDP-DAG can also react with G3P to form 
phosphatidylglycerol phosphate (PGP), as catalyzed by phosphatidylglycerophosphate synthase 
(PGPS), and the phosphate group of PGP is subsequently hydrolyzed by a phosphatase, known as 
protein tyrosine phosphatase, mitochondrial 1 (PTPMT1) to produce PG. CDP-DAG becomes 
committed to the cardiolipin synthesis pathway when it becomes PGP (33). Cardiolipin synthase 
(CLS) then catalyzes the condensation of PG to CDP-DAG, with the elimination of cytidine 
monophosphate (CMP), to produce immature cardiolipin (27).  
 
The pathway leading to the production of PE, PC, PS, or TAG begins with dephosphorylation 
of PA to produce DAG, as catalyzed by phosphatidic acid phosphohydrolase (PAP) also known as 
LIPIN1 (34). DAG can be used to produce PE through the addition of CDP-phosphoethanolamine, as 
catalyzed by CDP-ethanolamine: 1,2-diacylglycerol ethanolaminephosphotransferase (EPT), and to 
produce PC through the addition of CDP-choline, as catalyzed by CDP-choline: 1,2-diacylglycerol 
cholinephosphotransferase (CPT) (27). PS can be produced from PC in which the choline group is 
exchanged for a serine, as catalyzed by PS synthase-1 (PSS1), or from PE in which the ethanolamine 
group is exchanged from a serine, as catalyzed by PSS2 (35). To produce TAG, diacylglycerol 
acyltransferase (DGAT) catalyzes the conversion of DAG to TAG through esterification primarily at 
the sn-1 or sn-3 positions (36).  
 
GPATs and AGPATs incorporate fatty acids into PA, which is the precursor of all other 
glycerophospholipids and TAG. The acyl-CoA specificity of these initial Kennedy pathway enzymes 
therefore, determines the fatty acyl composition of newly synthesized phospholipids and TAG (37, 
38). After formation however, phospholipids can be remodelled to achieve a different final fatty acyl 
composition through the action of the Land’s cycle (28). For example, arachidonic acid and other 
³C20 polyunsaturated fatty acids are not commonly incorporated into phospholipids during de novo 
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synthesis, but rather during phospholipid fatty acid remodeling (38). This remodeling is mediated by 
enzymes of the membrane-bound O-acyltransferase (MBOAT) family and by some homologues of 
the AGPAT family of enzymes (AGPAT7, 8, 9, 11), which have turned out to have greater 
specificity for lysophospholipids other than LPA (38).  
 
Figure 1. The Kennedy pathway for the de novo synthesis of triacylglycerol and phospholipids. 
Fatty acid = FA.   
	
Glycerol-3-phosphate acyltransferases (GPATs) 
Two mitochondrial GPAT isoenzymes have been identified which localize to the outer 
mitochondrial membrane. GPAT1 preferentially acylates G3P with saturated fatty acyl-CoAs rather 
than unsaturated fatty acyl-CoAs, while GPAT2 shows no preference for the fatty acyl-CoA species 
donor (39, 40). In contrast, the microsomal GPATs localize to the endoplasmic reticulum and have 
activity ten times higher than that of mitochondrial GPATs (39-43). GPAT3 was originally called 
AGPAT10, but has been renamed based on a preference for G3P over LPA as the acyl acceptor (44). 
GPAT3 has been found to use long-chain fatty acyl-CoAs as donors, but shows no preference 
between saturated or unsaturated species (41, 44). GPAT4 was originally called AGPAT6 (42). It 
also showed no preference between saturated and unsaturated fatty acyl species (42, 45). 
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1-acylgylcerol-3-phosphate-O-acyltransferases (AGPATs)  
 Eleven members of the AGPAT family of enzymes have thus far been identified in humans 
and mice, with each containing two highly conserved catalytic acyltransferase motifs, NHX4D and a 
downstream proline residue, as well as two substrate (LPA) binding motifs, EGTR and FX2R (18, 30, 
44, 46-54). Most AGPATs have undergone subsequent renaming as additional information became 
available regarding substrate specificity, and now only five of these enzymes remain classified as 
true AGPATs that utilize LPA as their major fatty acyl acceptor. Others utilize G3P as their major 
acyl acceptor, thereby functioning as GPATs, or utilize other lysophospholipid species as acyl 
acceptors (42, 44, 45, 55-58). 
 
In 1997, AGPAT1, also known as LPAATα, became the first murine AGPAT isoform to be 
cloned and characterized (30). It was found to be a true AGPAT that utilizes only LPA as its major 
fatty acyl acceptor while preferring acyl-CoA donors with chain lengths from 12 to 18 carbons with a 
preference for C18:1 and  C18:2 (30, 46, 59). AGPAT1 also utilized C15:0, an odd chain fatty acid, 
for LPA acylation at a high rate (46). AGPAT1 is ubiquitously expressed in most tissues, with 
highest expression in the testis, pancreas, and adipose tissue, and it localizes to the endoplasmic 
reticulum (30, 46).  
AGPAT2, also as known as LPAATβ, also utilizes LPA as its major fatty acyl acceptor and 
C18:1-CoA as its major fatty acyl donor, with activity for 16:0-CoA and 18:0-CoA as well. (46, 60). 
AGPAT2 is localized to the endoplasmic reticulum and shows expression in a tissue-specific manner, 
with highest expression in adipose tissue and lower levels of expression in the liver and pancreas 
(46).  
AGPAT3 (LPAATg) is localized to the endoplasmic reticulum, nuclear envelope, and Golgi 
apparatus, and shows highest expression in the testes (47, 61, 62). It prefers oleoyl-CoA (18:1n-9-
CoA) and arachidonoyl-CoA (20:4n-6-CoA) as fatty acyl donors in the production of PA from LPA, 
but also shows acyltransferase activity towards lysophosphatidylcholine (LPC), 
lysophosphatidylserine (LPS), and lysophosphatidylinositol (LPI) in the presence of arachidonoyl-
CoA as the fatty acyl donor (47, 62).  
AGPAT4, also known as LPAATd, shows acyltransferase activity with LPA, but not with 
any other major lysophospholipids (48). AGPAT4 preferentially esterifies saturated fatty acyl-CoA 
species to LPA, particularly C12:0 and C20:0 (48, 63). It is localized to the outer mitochondrial 
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membrane and is most highly expressed throughout the entire brain, in both neurons and glial cells 
(48, 64).  
AGPAT5 is localized to the endoplasmic reticulum, nuclear envelope, and the mitochondria, 
with highest tissue expression in the testes (62). It shows similar substrate preference to AGPAT3, 
with a preference for oleoyl-CoA (18:1) over arachidonoyl-CoA, except that AGPAT5 utilizes 
lysophosphatidylethanolamine (LPE) as a fatty acyl acceptor, in addition to LPA, LPC, LPS, and LPI 
(62). 
 AGPAT6-11 have been shown to have AGPAT activity, catalyzing the acylation of LPA to 
PA. However, these enzymes have been shown to have much higher activity using other 
lysophospholipid substrates, and have been renamed for their other activities (44, 45, 55-58). 
AGPAT6 was first designated as LPAATζ but was shown to have predominant activity towards G3P 
instead of LPA and thus, is a microsomal GPAT that was renamed GPAT4 (45, 49).  AGPAT7 was 
first discovered as an LPA acyltransferase localized to the endoplasmic reticulum, but was later 
shown to have predominant acyltransferase activity towards LPE (50). AGPAT7 was therefore 
renamed acyl-CoA:lysophoshatidylethanolamine 2 (LPEAT2) and was found to have highest 
expression in the brain, with a broad preference for longer fatty acyl chain donors, such as C16:0, 
C18:0, C18:1, but no preference for the degree of saturation (55). AGPAT8 was originally 
discovered as acyl-CoA:lysocardiolipin acyltransferase 1 (ALCAT1), an enzyme localized to the 
mitochondria-associated membrane (MAM) showing activity with monolysocardiolipin (MLCL) and 
dilysocardiolipin (DLCL) as fatty acyl acceptors and linoleoyl-CoA (C18:3n-3) and oleoyl-CoA 
(18:1n-9) as acyl donors (56, 65). ALCAT1 also has activity towards LPA, although relatively low, 
and a preference for C16:0 and C18:0 fatty acyl-CoA donors, and was found to have highest 
expression in the heart (51). AGPAT9 was found to catalyze the acylation of LPC to PC as well as 
the formation of PA from LPA, albeit at low levels, and was therefore renamed acyl-
CoA:lysophosphatidylcholine acyltransferase 1 (LPCAT1) (52, 57). AGPAT9/LPCAT1 is localized 
to the endoplasmic reticulum and is highly expressed in the lung, in alveolar type II cells in 
particular, and in the spleen (52, 57). It prefers 18:1 as its major fatty acyl-CoA donor species (52). 
AGPAT10 was first identified as GPAT3 due to its high G3P acylation activities (44). However, it 
was later shown to also have activity towards the acylation of LPA, using 18:1 as the acyl donor. 
AGPAT10/GPAT3 localizes to the endoplasmic reticulum and shows highest expression in adipose 
tissue followed by the testis and kidney (44). AGPAT11 was first discovered as both acetyl-
CoA:lyso-platelet-activating factor acetyltransferase (LysoPAFAT), due to its ability to produce 
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platelet-activating factor (PAF), and LPCAT2, due to its acyltransferase activity towards LPC and 
high sequence homology towards LPCAT1 (58). When AGPAT11 was cloned, it was found to have 
the same mRNA coding sequence as LPCAT2/lysoPAFAT, and to preferentially acylate LPA using 
18:1-CoA. AGPAT11 localizes to the endoplasmic reticulum and is highly expressed in the lung, 
spleen and in leukocytes (53).  
Table 1. Summary of the AGPAT isoforms  
Isoform Preferred 
lysophospholipid 
acceptor  
Subcellular 
expression 
Fatty acyl-CoA 
donor 
Tissue 
Expression  
1 LPA ER C18:1-CoA 
C18:2-CoA 
C15:0-CoA 
 
Testis, pancreas, 
adipose tissue 
2 LPA ER C18:1-CoA Adipose tissue, 
pancreas, liver 
3 LPA, 
LPC/LPI/LPS 
ER 
Nuclear envelope  
Golgi apparatus  
 
C18:1-CoA 
C20:4-CoA 
Testis, pancreas, 
kidney 
4 LPA Mitochondria C18:1-CoA Brain, heart, 
adipose tissue 
5 LPA, 
LPC/LPI/LPS/LPE 
ER 
Mitochondria 
Nuclear envelope 
  
C18:1-CoA Testis, prostate 
6 (GPAT4) G3P ER C16:0-CoA 
C18:1-CoA 
BAT, Mammary 
epithelium  
7 (LPEAT2)  LPE ER C16:0-CoA 
C18:1-CoA 
Brain 
8 (ALCAT1) MLCL, DLCL MAM C18:1-CoA 
C18:3-CoA 
Heart 
9 (LPCAT1) LPC ER C18:1-CoA Lung, spleen 
10 (GPAT3) G3P ER C18:1-CoA Adipose tissue, 
testes, kidney 
11 (LPCAT2)  LPC  ER C18:1-CoA Lung, spleen, 
kidney  
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AGPATs and GPATs in white adipose tissue 
 Several GPATs and AGPATs are known to be expressed in white adipose tissue and have 
been linked to the regulation of TAG production, to the differentiation of adipocytes, and to 
modulation of various pathologies including lipodystrophy, diabetes, and hepatic steatosis. In 
particular, GPAT3, GPAT4/AGPAT6, and AGPAT2 are all highly expressed in white adipose tissue 
and have been studied in either overexpression or gene ablation models in this tissue (41, 66-69).  
 
GPAT3 has been suggested to be the predominant GPAT in differentiated 3T3-L1 cells and 
in WAT (41, 66). GPAT3 mRNA increased 60-fold during 3T3-L1 differentiation into mature 
adipocytes and was shown to function in the TAG biosynthesis branch of the Kennedy pathway, 
since overexpression of GPAT3 in HEK293 cells leads to increased incorporation of radiolabelled 
oleic acid into TAG, but not phospholipids, compared to controls (41). In Gpat3-/- mice, total GPAT 
activity in WAT was reduced by 80% compared to wildtype controls, and when fed a high fat diet, 
GPAT3-deficient mice showed lower body weights and reduced adiposity, increased energy 
expenditure, enlarged livers, and higher free cholesterol, cholesteryl esters, and TAG in the liver, 
suggesting that a lack of GPAT3 may impair the ability to store excess energy in adipose tissues (66).  
 
GPAT4/AGPAT6 has also been shown to play a critical physiological role in the 
accumulation of TAG in white adipose tissue. Gpat4/Agpat6-/- mice show reduced body weight and 
TAG content, small gonadal WAT adipocyte size, and subcutaneous lipodystrophy (67). 
Gpat4/Agpat6-deficient mice were also shown to be resistant to both diet-induced and genetically-
induced obesity, as seen by the maintenance of lower body weights when these animals were fed a 
high fat diet or were crossed onto the genetically obese leptin-deficient ob/ob background (67).  
The role of AGPAT2 in the production and regulation of TAG synthesis was discovered 
originally from studies in patients with AGPAT2 mutations. These individuals have a form of 
congenital generalized lipodystrophy (CGL), also known as Berardinelli-Seip syndrome, which is an 
autosomal recessive disorder characterized by a lack of adipose tissue, insulin resistance, 
hypertriglyceridemia, hepatic steatosis, and early onset of diabetes (68). Although the exact 
mechanism by which AGPAT2 mutations cause lipodystrophy has yet to be elucidated, AGPAT2 has 
been shown to be imperative for both lipogenesis and adipogenesis. Agpat2 is upregulated 40-fold 
during adipocyte differentiation and Agpat2 knockdown results in delayed adipocyte differentiation 
and impaired TAG synthesis and storage (69). These findings indicate the importance of several 
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GPAT/AGPAT family members in adipocyte differentiation, TAG synthesis, and TAG storage. At 
present however, understanding of the role of AGPATs in adipose tissue biology is far from 
complete. Evidence indicates expression of other AGPATs in white adipose tissue, likely suggesting 
a functional role for additional AGPATs in maintaining healthy white adipose tissue and in 
modulating adipocyte-regulated metabolic disease.  
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Chapter 3: Rationale, Objectives, and Hypotheses 
	
Rationale 
The role of Agpat4 in vivo has yet to be fully determined.  To date, three studies have 
published on the in vitro characterization of AGPAT4. Lu et al. (2005) showed that recombinant 
murine AGPAT4 synthesized in rabbit reticulocyte lysates had AGPAT activity, as measured by the 
amount of PA produced, although no AGPAT activity was observed in COS-1 cells transfected with 
the mammalian expression vector pcDNA3.1-mAGPAT4 (18). Eto et al. (2014) measured the 
lysophosphatidic acid acyltransferase capabilities of AGPAT4 in the microsomal fractions of Chinese 
hamster ovary (CHO)-K1 cells overexpressing the enzyme and found that it had AGPAT capabilities, 
preferentially esterifying LPA with long chain polyunsaturated fatty acids, especially 
docosahexaenoic acid (DHA, 22:6n-3) (70). Recently, Bradley et al. (2015) clarified prior ambiguous 
findings on AGPAT4 in a series of studies on the in vitro and in vivo role of this enzyme. Assays 
conducted in lysates from Sf9 cells infected with baculoviral Agpat4 confirmed that AGPAT4 has in 
vitro acyltransferase activities towards LPA as an acyl acceptor, but not towards LPC, LPE, LPS, 
LPG, LPI, MLCL, or DLCL. Overexpression of AGPAT4 in Sf9 cells increased the endogenous 
cellular PI content by 72% compared to controls. In mice, Agpat4 ablation significantly decreased the 
brain content of PI by 52%, PC by 39%, and PE by 32% compared to wildtype littermates, without 
changing PA, PS, PG or CL content (48). Interestingly, the levels of PA in the brains of the Agpat4-/- 
mice were identical to their wildtype littermates due to a compensatory upregulation of the other 
AGPAT homologs (1-5), but this was not sufficient to normalize downstream phospholipid synthesis. 
This indicated that the production of PA from LPA, as catalyzed by AGPAT4 in the brain, is shunted 
into specific downstream Kennedy pathway derivatives for the production of brain PC, PE, and PI 
and, therefore, AGPAT4 is an indirect, but essential, regulator of these phospholipids in the brain 
(48). Although Agpat4 is most highly expressed in the brain, it does show substantial expression in 
both the heart and in perirenal WAT as well (Fig. 2).  
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Figure 2. Agpat4 expression in murine tissues. Real-time (RT)-PCR showing murine Agpat4 
expression in various tissues and subsections of the central nervous system (CNS). R.O.B. = rest of 
brain.  
 
The role of AGPAT4 in white adipose tissue has yet to be experimentally determined.  We 
proposed to characterize the role of AGPAT4 in white adipose tissue using a gene ablation model 
where three major white adipose tissue regulatory processes were studied: adipogenesis, lipogenesis, 
and lipolysis.  
 
Objectives 
 The primary objectives of this thesis were to characterize the in vivo biochemical and 
physiological role of AGPAT4 in the formation and maintenance of white adipose tissue. Using a 
gene ablation model of Agpat4, measures of whole body physiology, including measures of food 
intake, activity and energy metabolism, were determined. The epididymal and perirenal WAT depots 
were also assessed for weight and morphology as well as mRNA and protein expression of various 
adipogenic, lipolytic, and glycerolipid synthesis and remodeling genes, as well as lipolytic and 
lipogenic activities.  
The first objective was to characterize the expression of AGPAT4 in various adipose tissue 
depots. Specific WAT depots, including epididymal, perirenal, retroperitoneal, and inguinal, as well 
as the subscapular brown adipose tissue (BAT) depot, from C57Bl/6J mice, were assessed for 
AGPAT4 mRNA expression relative to a loading control. Expression of Agpat4 was also measured 
in the wildtype and knockout mice of the epididymal and perirenal white adipose depots to confirm 
the absence of Agpat4 in the Agpat4-/- mice.  
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The second objective was to determine the effect of loss of AGPAT4 on adipose tissue depot 
masses and whole body physiology. This was determined by excision of specific adipose tissue 
depots at necropsy and by using the Comprehensive Laboratory Animal Monitoring System 
(CLAMS). 
The third objective was to assess the role of AGPAT4 in the formation of phospholipids and 
TAG in epididymal and perirenal WAT. This was done by determining the quantity and composition 
of individual classes of phospholipids and TAG in epididymal and perirenal white adipose tissue 
depots using thin layer chromatography (TLC) followed by gas chromatography (GC).  
The fourth objective was to assess the requirement for Agpat4 in adipogenesis in both the 
epididymal and perirenal WAT depots. This was evaluated by determining mRNA expression of 
genes involved in the differentiation of adipocytes in Agpat4-/- mice as compared with wildtype mice. 
Furthermore, cell size was estimated from fixed sections of adipose depots. 
The fifth objective was to determine the effect of Agpat4 loss on lipogenesis in epididymal 
and perirenal WAT. This was done by assessing the mRNA of various lipogenic regulators as well as 
utilizing immunoblotting to measure the expression of various proteins involved in fatty acid 
synthesis in the epididymal and perirenal adipose depots of Agpat-/- and wildtype mice.  
 The sixth objective was to determine the effect of loss of Agpat4 on the regulation of 
lipolysis in the epididymal and perirenal white adipose tissues. This was done through the assessment 
of protein expression of various lipolysis regulators in these depots. In addition, lipolytic activity was 
directly assessed using an in vitro radiochemical TAG hydrolysis assay with tissue extracts from 
Agpat4-/- and wildtype mice, and using an in situ assay in which fatty acid and glycerol release was 
measured from adipose tissue explants incubated in a physiological buffer. 
 The seventh objective was to measure the effect of loss of Agpat4 on expression of other 
AGPAT isoforms (1, 2, 3, and 5) in both wildtype and Agpat4-/- mice to determine if compensation is 
observed. 
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Hypotheses 
	
 The hypotheses of this study are: 
1. Agpat4 expression will be ubiquitous amongst all white adipose tissue depots and will not be 
expressed in Agpat4-/- mice. 
2. Agpat4 ablation will result in a decrease in white adipose tissue masses, and whole body 
weights, as a result of reduced triacylglycerol synthesis.  
3. Agpat4 ablation will result in a decrease in the production of specific phospholipids, in 
epididymal and perirenal WAT, that may include PI, PC, and PE, and will also result in a 
decrease in TAG that is the major complex glycerolipid in adipose tissue. 
4. Agpat4 ablation will decrease differentiation in both the epididymal and perirenal adipose 
tissue depots, since TAG production is a critical signalling process in adipocyte 
differentiation, and TAG synthesis is expected to decrease in white adipose tissue. 
5. Agpat4 ablation will result in a decrease in lipogenesis in epididymal and perirenal WAT as 
AGPATs are responsible for the formation of PA, the branching point in which phospholipids 
and TAG are produced.  
6. Agpat4 ablation will result in a decrease in lipolytic activity as a compensatory mechanism in 
response to the expected decrease in TAG production and white adipose tissue mass. 
7. Agpat4 ablation will result in a compensatory induction of other Agpats (1, 2, 3, and 5) in 
epididymal and perirenal WAT.  
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Chapter 4: Methods  
	
Animals and Knockout Model 
Adult male Agpat4-/- mice, aged 9 to 12 weeks old, were used with age-matched wildtype 
littermates as controls in all experiments. All mice were housed in a temperature and humidity 
controlled environment on a 12:12 hour reversed light/dark cycle and standard rodent chow and 
water were provided ad libitum. All animal procedures were approved by the University of Waterloo 
Animal Care Committee.  
Heterozygous Agpat4-/- mouse embryos (B6;129S5-Agpat4tm1Lex/Mmucd) were produced by 
Lexicon Genetics/Genentech through homologous recombination targeting coding exons 4, 5, and 6 out 
of the 9 Agpat4 exons (NCBI accession NM_026644.1). The targeted mutation was generated in mouse 
129S5/SvEvBrd embryonic stem cells with a LacZ/neomycin selection cassette and positive clones were 
identified by Southern blotting as previously reported (71). Progeny from clones 1A9 and 1P9 were 
crossed with C57BL/6J albino mice, generating F1 heterozygous animals, were cryorevived at the Mutant 
Mouse Regional Resource Center, and sent from the University of California at Davis to the University of 
Waterloo. Male and female heterozygous littermates were crossed to achieve F2 wildtype, heterozygous 
and homozygous mutant progeny. Mice used in experiments are produced by continuous backcrossing 
of heterozygotes.  
 
DNA Isolation and Genotyping 
DNA was isolated from ear punches after performing an overnight proteinase K digestion in 
which 400 µL of 1.0 mg/ml proteinase K in warmed lysis buffer (0.5% SDS, 0.1M NaCl, 0.05M Tris 
(pH 8.0), 2mM EDTA) was added to the ear punches and incubated at 63˚C for 24 hours. 75 µL of 
8M potassium acetate and 500 µL of chloroform was added followed by vortexing at high speed for 
5 to 10 minutes. The samples were centrifuged at 1,000 rpm for 5 minutes and the aqueous layer was 
retrieved. Two volumes of 100% ethanol were added, mixed through inversion, and centrifuged at 
14,000 rpm for 20 minutes at 4˚C. The resulting pellet was air dried and eluted in water. DNA 
concentrations and purity were determined using a Nanodrop-2000 spectrophotometer (Thermo 
Scientific, Waltham, PA) and sample concentrations were subsequently adjusted to 250ng/µl.  
Genotyping was determined by visualization of amplicons of the correct size in 1.0% agarose 
gels run in tris-acetate-EDTA (TAE) buffer following PCR amplification of DNA using primers 
specific for a region present only in the wildtype animals (located within intron 5) or primers specific 
to the recombined targeted region (crossing the end of the targeted sequence into the beginning of the 
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wildtype sequence in intron 6) (Fig. 3). PCR was performed using 1 µL of DNA with the following 
primers: wildtype (forward: 5’-TTA GCA TAG TGG GCG AAG TTC-3’, reverse: 5’-GGT AGT 
GGC CAA GTT AAT AGT CCT-3’; 216 bp band produced only when the intact gene is present) and 
Agpat4-/- (forward: 5’-GCA GCG CAT CGC CTT CTA TC-3’, reverse: 5’-CTC CCA TTT CTA 
GGA AGG AAG CAG-3’; 344 bp band produced only when Agpat4 gene has been disrupted). 
Amplification was performed in a T100 Thermal Cycler (BioRad, Hercules, CA) with the following 
conditions: 94˚C for 5 minutes, 39 cycles of 94 ˚C for 1 minute, 58 ˚C for 1 minute, 72 ˚C for 30 
seconds, followed by 72 ˚C for 10 minutes.  
 
A 
 
 
B 
 
Figure 3. Agpat4 gene ablation in mice. A, A LacZ/Neo fusion cassette replaced exons 4, 5, and 6, 
removing the catalytically critical EGTR motif in exon 5. Arrows indicate primers used for 
genotyping and letters indicate unique restriction sites where B = BgIII, H = HindIII, E = EcoRV 
site. B, Example genotyping analysis showing amplicon present only in wildtype mice (top) and 
amplicon present only in Agpat4-/- mice (top). W = wildtype, K = Agpat4-/-, H = heterozygote.  
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Adipose tissue depot collection 
 Agpat4-/- and wildtype mice were euthanized via cervical dislocation, whole body weights 
were taken, and mice were placed in a dorsal position. An incision was made from the sternum to the 
pelvis in the sagittal plane and the gonadal white adipose depot in the lower pelvis, surrounding the 
reproductive organs and termed epididymal adipose tissue, was dissected out. The organs of the 
abdominal cavity were removed to expose the kidneys. The kidneys were excised and the white 
adipose tissue surrounding the organ, termed perirenal, was removed. The white adipose tissue in the 
abdominal cavity, dorsal to the kidneys and termed retroperitoneal, was then exposed and excised. A 
subcutaneous white adipose depot, termed inguinal, was excised by peeling away the skin in the hind 
region to expose the adipose tissue directly beneath the surface. Following, the mice were placed in a 
ventral position and the adipose tissue between the shoulder blades was dissected out. The white 
adipose tissue was removed from the sample, exposing the depot termed the subscapular BAT (Fig. 
4). All tissues were immediately weighed and flash frozen in liquid nitrogen. 
 
Figure 4. Excised adipose depot locations  
 
Comprehensive Laboratory Animal Monitoring System (CLAMS)  
 An Oxymax Comprehensive Laboratory Animal Monitoring Systems (CLAMS) (Columbus 
Instruments, Columbus, OH) was used for two trials of 72 hours each. Oxymax is an open circuit 
indirect calorimeter used to determine Respiratory Exchange Ratio (RER), heat production, fat 
oxidation, carbohydrate oxidation, food consumption, total activity, dual beam movement, Z axis 
movement, daily average VO2, and VO2 while awake and sleeping. Animals were housed 
individually and a 2 hour acclimation period in the metabolic chamber occurred prior to monitoring 
over a 72 hour period under consistent environmental temperature (22˚C).  RER was calculated using 
the ratio of carbon dioxide (VCO2) to oxygen consumption (VO2) and can indicate fat as the primary 
substrate (RER=0.7) or carbohydrate as the primary substrate (RER=1.0). Heat was determined using 
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the product of the calorific value (derived from the RER) and volume of oxygen consumed. Food 
consumption was determined by weighing the chow before and after measurements, and activity was 
determined through infra-red beam breaks. 
 
RNA Isolation and Reverse Transcription (RT)-PCR 
Total RNA was isolated from adipose tissues that were disrupted in TRIzol® reagent (Sigma-
Aldrich, Oakville, ON) added at a concentration of 1 ml/£100 mg, using a Polytron® homogenizer 
set at maximal velocity (VWR, Radnor, PA). Samples were then incubated at room temperature for 
an additional 5 minutes to ensure nucleoprotein complex dissociation. Chloroform (0.2 ml per mL of 
TRIzol® reagent used initially) was added and samples were vigorously shaken for 15 seconds, 
which was followed by incubation at room temperature for 2 minutes. Samples were centrifuged at 
12,000 x g for 15 minutes at 4˚C. The upper aqueous phase, containing RNA, was added to a fresh 
tube and 0.5 mL of isopropanol was added per mL of TRIzol® reagent used initially. This was 
followed by incubation again at room temperature for 10 minutes to allow the RNA to precipitate. 
The samples were then centrifuged at 12,000 x g for 10 minutes at 4˚C to pellet the RNA. The 
supernatant was removed and the RNA pellet was washed using 1 mL of 75% ethanol per 1 mL of 
initial TRIzol® reagent. The samples were then vortexed and centrifuged at 7,500 g for 5 minutes at 
4˚C. The ethanol was removed, the pellet was left to air dry at room temperature for 5-10 minutes 
and then re-suspended in 30 µl in deionized water. The solutions were incubated at 60˚C for 10 
minutes to facilitate dissolution and subsequently stored at -80˚C. 
 Concentrations and purity of the RNA was determined using a Nanodrop-2000 
spectrophotometer (Thermo Scientific) and RNA concentrations were adjusted to 2.5 µg/µl. 
Complementary DNA (cDNA) was generated through the reverse transcription of RNA using a Bio-
Rad T100 Thermal Cycler. RNA was mixed with 4.2 µl double distilled H2O (ddH2O), 2 µl of 10x 
RT buffer, 0.8 µl 100 mM dNTPs, 2 µl 10x RT random primers, and 1 µl reverse transcriptase. 
Reverse transcription occurred at the following settings: 25˚C for 10 minutes, 37˚C for 2 hours, and 
85 ˚C for 5 seconds. The cDNA was stored at -20 ˚C.  
 
Quantitative PCR (qPCR) and Semi-quantitative PCR 
 Quantitative qPCR (qPCR) was performed using a Bio-Rad CFX96 Touch™ Real-Time PCR 
Detection System. cDNA was mixed with 1.5 µl ddH2O, 7.5 µl SsoFast EvaGreen master mix (Bio-
Rad), 0.5 µl of the forward primer and 0.5 µl of the reverse primer (25 pM final concentration). 
Amplification occurred with the conditions: 95˚C for 2 minutes, 40 cycles of 95˚C for 10 seconds, 
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60˚C for 20 seconds, followed by a melt curve to verify a single amplicon. The relative quantity of 
the gene of interest (ΔCt) was calculated as ΔCt =[Ct (gene of interest) - Ct (housekeeping gene)] with 
18s used as the housekeeping gene for normalization. The relative expression of the gene of interest 
in the different white adipose depots (ΔΔCt) of the knockout animals was calculated relative to the 
same gene in the same depot in the wildtype animals as ΔΔCt = 
!"#$	&'(')*(+,-+./!"#$	&'(')0123/45'	. Semi-quantitative 
PCR was performed in a T100 Thermal Cycler (Bio-Rad) with the following conditions: one cycle of 
94˚C for 4 minutes, followed by 30 cycles of 94 ˚C for 30 seconds, 58 ˚C for 30 seconds, 72 ˚C for 1 
minute, followed by a final extension of 72 ˚C for 10 minutes. 1 µl of cDNA was mixed with 2 µl of 
10x buffer with MgCl2, 0.4 µl of 10 mM dNTPs, 1 µl of the forward primer, and 1 µl of the reverse 
primer. Following PCR amplification, amplicons were resolved in a 1.0% TAE-agarose gel with 
ethidium bromide for visualization under ultraviolet light. Quantification occurred relative to the 
expression of 18S. All primers are listed in table 1. 
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Table 2. PCR primers 
Gene Direction Sequence Product Size 
Agpat1 Forward 
Reverse 
5’- AGA CCT TGC TCA CCC AGG AT-3’ 
5’ GAT GGG GAT GAT GGG GAC CT-3’ 
134 bp 
Agpat2 Forward 
Reverse 
5’-CCGTGGTGTACTCGTCTTTCT-3’ 
5’-CAGACCATTGGTAGGGACAGC-3’ 
107 bp 
Agpat3 Forward  
Reverse 
5’-GCT TCG TCC TGG GTG TCT TT-3’ 
5’-GTT GCC ATA GCT GGA GCC TT-3’ 
137 bp 
Agpat5 Forward 
Reverse 
5’-GGA CAT GTG CGC TAC GTA CT-3’ 
5’-AGA TAC ATC GGT GTT CCT GCG-3’ 
167 bp 
Atgl Forward 
Reverse 
5’-AACGCCACTCACATCTACGG-3’ 
5’-GCCTCCTTGGACACCTCAATA-3’ 
113 bp 
Cdipt Forward 
Reverse 
5’-GATCGACCTGTCTGGGAACC-3’ 
5’-TTTCCAGCACACAGGGTGAA-3’ 
78 bp 
Cds1 Forward 
Reverse 
5’-TGGACATGGCGGGATAATGG-3’ 
5’-TGGAGCACTTTGCTGGGATT-3’ 
111 bp  
Cds2 Forward 
Reverse 
5’-GGGTTCTTCGCCAGTGGATT-3’ 
5’-AAGCGATCCATGATGCCTCC-3’ 
89 bp 
C/ebpα Forward 
Reverse 
5’-GCAAAGCCAAGAAGTCGGTG-3’ 
5’-TCTCCACGTTGCGTTGTTTG-3’ 
114 bp 
C/ebpβ Forward 
Reverse 
5’-AAGCTGAGCGACGAGTACAAGA-3’ 
5’-GTCAGCTCCAGCACCTTGTG-3’ 
116 bp 
Cept1 Forward 
Reverse 
5’-TTGTACTGTGGCAGGGACCA-3’ 
5’-TGTTCCTGCTATGGTTGACCC-3’ 
97 bp 
Chpt1 Forward 
Reverse 
5’-ACTGTCTTTATTGGGCCAGGT-3’ 
5’-GACCATTGCTATCCACAGAACA-3’ 
90 bp 
Dgat1 Forward 
Reverse 
5’-CTGGATTGTGGGCCGATTCT-3’ 
5’-ATACATGAGCACAGCCACCG-3’ 
94 bp 
Dgat2 Forward 
Reverse 
5’-AAGACATCGACCTGTACCATGC-3’ 
5’-CTCAGTCTCTGGAAGGCCAAA-3’ 
92 bp 
Fabp4 Forward 
Reverse 
5’-GTGGGATGGAAAGTCGACCA-3’ 
5’-CATAACACATTCCACCACCAGC-3’ 
70 bp 
Fat/cd36  Forward 
Reverse 
5’-ACTGTGGCTAAATGAGACTGGG-3’ 
5’-ACCATGCCAAGGAGCTTGAT-3’ 
93 bp 
Hsl Forward 
Reverse 
5’-GGAGTCTATGCGCAGGAGTG-3’ 
5’-GCTTCTTCAAGGTATCTGTGCC-3’ 
80 bp 
Iplaβ Forward 
Reverse 
5’-CCTTTCCATTACGCTGTGCAA-3’ 
5’-GACTCACGGCTTGGTTGTT-3’ 
103 bp 
Iplaγ Forward 
Reverse 
5’-CAAAGACAAGAAGGCAGAGGAG-3’ 
5’-TAAGGCCTGAACTAAGGCTCG-3’ 
106 bp 
Lipin1 Forward 
Reverse 
5’-CCTTAGGGAGCCGGAAGACT-3’ 
5’-ATTGTTGGCGACTGGTCACT-3’ 
91 bp 
Pgs1 Forward 
Reverse 
5’-GGGTCCAGCTCCAGGAATAC-3’ 
5’-TAGGAGAGCCAATCAGCGTG-3’ 
111 bp 
Pka Forward 
Reverse 
5’-AATCGTCTCTGGGAAGGTGC-3’ 
5’-GACCCCGTTCTTGAGGTTCC-3’  
118 bp 
Pparγ Forward 
Reverse 
5’-CACAATGCCATCAGGTTTGG-3’ 
5’-GCTGGTCGATATCACTGGAGATC-3’ 
82 bp 
Pref1 Forward  
Reverse 
5’-GACAGGCCATCTGCTTCACC-3’ 
5’-GTTGTAGCGCAGGTTGGACA-3’ 
116 bp 
18s Forward 
Reverse 
5’-GATCCATTGGAGGGCAAGTCT-3’ 
5’-AACTGCAGCAACTTTAATATACGCTATT-3’ 
79 bp 
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Paraffin Embedding and Hematoxylin and Eosin (H&E) Staining 
 White adipose tissue depots were collected from Agpat4-/- and wildtype control mice and 
embedded in paraffin. Briefly, fresh tissues were fixed in 4% paraformaldehyde for 48 hours at 4˚C 
and subsequently placed in embedding cassettes. Dehydration followed in which the cassettes, 
containing the samples, were washed with 70% ethanol twice for 1 hour each, with 80% ethanol 
twice for 1 hour each, 95% ethanol twice for 1 hour each, 100% ethanol 3 times for 1 hour each, and 
xylene three times for 1 hour each. The cassettes were then placed in paraffin wax for 1 hour, 
followed by an overnight incubation in a fresh change of paraffin wax, and another 1 hour incubation 
in fresh paraffin before embedding in paraffin blocks. Following embedding, the samples were cut 
into 6µm sections using a microtome and carefully transferred onto microscope slides where they 
were incubated overnight at 40˚C to facilitate adherence to the slide. Sample rehydration occurred 
next, where slides were washed with xylenes 3 times for 5 minutes, 100% ethanol 2 times for 2 
minutes, 95% ethanol for 1 minute, 70% ethanol for 1 minute, and running water for 1 minute. 
Hematoxylin was then added and left on the slides for 3 minutes, followed by a 1 minute wash in 
running water, incubation in Scott’s solution (5g MgSO4, 0.33g Na2CO3, 500ml tap water) for 1 
minute, a 1 minute wash in running water again, 80% ethanol for 1 minute, and then 95% ethanol for 
1 minute. Eosin was added and left on the slides for 3 minutes, followed by a brief 95% ethanol 
wash, 100% ethanol 3 times for 1 minute, and 3 changes of xylene for 2 minutes. Microscope slides 
were then be imaged and cross-sectional areas quantified using Image J software (72). Five separate 
fields from four different mice were quantified.  
 
Protein Extraction and Immunoblotting 
 White adipose tissue depots were collected from Agpat4-/- mice and homogenized on ice in 
lysis buffer (50 mM Tris, pH 7.4, 1 mM EDTA, 0.1 M sucrose, 5mM sodium fluoride, 10 mM 
sodium orthovanadate, with protease inhibitor cocktail (1:100)) using a Polytron® homogenizer 
(VWR). Centrifugation occurred at 10,000 x g for 10 minutes at 4˚C and the supernatant was 
collected and sonicated on ice at 65 amp for 6 seconds, 3 times. Protein concentration was 
determined using a bicinchoninic acid (BCA) assay in which 100 µl of 4% copper sulfate in BCA 
1:50 was added to 5 µl of protein sample followed by incubation at 37˚C for 30 minutes. Absorbance 
was measured at 527 nm. Protein concentration was determined using a bovine serum albumin (BSA) 
standard curve.  
 Equivalent masses of total protein were mixed with 6X protein loading dye (375 nM Tris 
HCl, 9% SDS, 50% glycerol, 0.03% bromophenol blue) and heated for 5 minutes at 95˚C. Samples 
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were electrophoresed through Bio-Rad 10% TGX Stain-Free FastCast Acrylamide gels at 200 V for 
30 minutes, followed by a transfer onto a nitrocellulose membrane at 0.35A for 90 minutes. Blocking 
was performed using a 3% blocker (w/v) in TBST (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% 
Tween-20) for 1 hour. The nitrocellulose membranes were then incubated at 4˚C overnight with a 
primary antibody, at 1:1000 in 3% blocker (w/v) in TBST, against the protein of interest. The 
following antibodies, purchased from cell signaling (Beverly, MA), were used: ATGL, HSL, 
phosphorylated (P)-HSL S563, P-HSL S565, P-HSL S660, perilipin, AMPK α, acetyl-CoA 
carboxylase (ACC), P-ACC S79, and FAS. The membranes were washed 3 times for 15 minutes in 
TBST and incubated for 1 hour with a horseradish peroxidase (HRP)-conjugated secondary antibody 
in TBST with 3% blocker (w/v). The membranes were washed 3 times for 15 minutes followed by 
the addition of LuminataTM Crescendo HRP substrate chemiluminescence reagent. Imaging occurred 
using a Bio-Rad ChemiDocTM Touch Imaging system and the size of proteins of interest were 
determined using a Bio-Rad precision plus proteinTM standard with a 10-200 kDa wide range. Equal 
protein loading was determined through quantification of total protein by imaging a stain-free gel to 
determine total protein content per lane. Skim milk powder was used as a blocker for ATGL and 
BSA was used as a blocker for the remainder of the proteins.  
 
Extraction of Adipose Tissue Lipids and Lipid Analysis  
 White adipose tissue depots were collected from Agpat4-/- mice and total lipids were extracted 
as described by Folch et al., in 1957 (73). 50 mg samples were homogenized in glass tubes in 2:1 
(v/v) chloroform:methanol using a Polytron® homogenizer (VWR) and 500 µl of sodium phosphate 
was added, followed by 3x inversion and centrifugation at 3,000 rpm for 5 minutes. The organic 
layer was collected and 2 ml of chloroform was added to the remaining layers, and this was followed 
by centrifugation at 3,000 rpm for 5 minutes and a second collection of the organic layer. The 
organic layers were pooled, dried with nitrogen gas to reduce the volume, and then applied to a silica 
gel G plate (Analtech, Newark, NJ) with a solvent front containing hexane:diethyl ether:glacial acetic 
acid (80:20:2, v/v/v) for neutral lipid separation by thin layer chromatography. Bands were visualized 
by spraying the plates with 2’,7’-dichlorofluorescein. The band corresponding to TAG, as determined 
by comparison to a known TAG standard, was scraped for analysis of fatty acid content and 
composition by gas chromatography. The band corresponding to polar lipids, remaining at the origin, 
was also scraped, followed by lipid extraction. The resulting organic layer was dried with nitrogen 
gas to reduce the volume and applied to a silica H plate (Analtech) that was then resolved using a 
solvent mixture of chloroform:methanol:isopropanol:0.25% KCL:triethylamine (30:9:25:6:18, 
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v/v/v/v/v) to separate individual phospholipid classes. The bands corresponding to these 
phospholipid classes were identified using known standards (Avanti Polar Lipids, Alabaster, AL) and 
scraped. The total lipid extraction procedure was performed with the addition of an internal standard 
(10 µg 22:3n-3 methyl ester per ml of 2:1 chloroform:methanol) in order to estimate recovery and an 
antioxidant was added to prevent destruction of unsaturated fatty acids (50 µg/ml BHT). Gas 
chromatography with flame ionization detection was performed to determine the fatty acid 
composition of each class of phospholipids as described by Metherel et al. in 2009 (74). These values 
were also used to estimate the total concentration of each phospholipid within the tissue. Briefly, 
transesterification using 14% boron trifluoride in methanol (Thermo Fisher Scientific) occurred with 
hexane on a 95˚C heat block for 1 hour to convert lipid fatty acyl chains into fatty acid methyl esters. 
Analysis was then performed using a Varian 3900 gas chromatograph equipped with a DB-FFAP 
15m x 0.1mm injected dose x 0.10µm film thickness, nitroterephthalic acid modified, polyethylene 
glycol, capillary column (J&W Scientific from Agilent Technologies, Mississauga, ON) with 
hydrogen as the gas carrier. A volume of 1 µl of each sample was introduced by a Varian CP-8400 
autosampler into the injector heated to 250˚C with a split ratio of 200:1. The temperature began at 
150˚C with a 0.25 min hold which was followed by a 35˚C/min ramp to 200 ˚C, an 8˚C /min ramp to 
225˚C with a 3.2 min hold and finally, an 80˚C/min ramp up to 245˚C with a 15 min hold. The 
temperature of the flame ionization detector was 300˚C with air and nitrogen make-up gas flow rates 
of 300 and 25 mL/ min, respectively, and a sampling frequency of 50 Hz. An external reference 
standard (GLC-462, Nu Chek Prep, Elysian, MN) was used to identify individual fatty acid peaks. 
 
Radiochemical in vitro triolein hydrolase assay 
 Protein lysates containing 100 µg of protein in 100 µl of lysis buffer were added to 100 µl of 
a reaction mixture containing 300 µM triolein with [9,10-3H(N)]triolein (0.15 µCi per reaction), 25 
µM egg yolk lecithin, 2% BSA (w/v), 100 µM sodium taurocholate, 50 mM potassium phosphate 
(pH 7.2), and 1 mM DTT. The reaction mixture was incubated at 37˚C for 1 hour and quenched by 
the addition of 0.25 ml of 2:1 chloroform:methanol. Total lipid extraction occurred using the method 
as described by Bligh and Dyer in 1959 (75). Briefly, 0.250 ml of chloroform was added to the 
quenched mixture, followed by vortexing for 30 seconds, the addition of 0.250 ml ddH2O, vortexing 
for 30 seconds, and centrifugation for 5 minutes at 1000 x g. The organic phase was retrieved, dried 
with nitrogen gas, and applied to a silica gel G plate with a solvent front containing hexane:diethyl 
ether: glacial acetic acid (80:20:2, v/v/v) for neutral lipid separation. The band corresponding to non-
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esterified fatty acids (NEFA), as determined by known standards, was scraped and subject to liquid 
scintillation counting for quantification of hydrolyzed fatty acids.  
 
In situ lipolysis assay 
 Epididymal and perirenal WAT explants were assayed for glycerol and free fatty acid release, 
as previously described (76). Briefly, 50 mg samples of tissue from overnight-fasted mice were 
excised and incubated immediately in 500 µl of Krebs-Ringer solution (0.12 M NaCl, 4.7 mM KCl, 
2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4) with 20 mM HEPES, 2% fatty acid-free BSA, and 
0.1% glucose. Aliquots were measured at time point 0, 30 minutes, 1 hour, 2 hours, and 4 hours, for 
fatty acid and glycerol release using a NEFA Reagent (Wako Diagnostics, Mountain View, CA) and 
Free Glycerol Reagent (Sigma-Aldrich), respectively.  
 
Triacylglycerol and non-esterified fatty acids plasma assays  
 Blood samples were obtained from Agpat4-/- mice and their wildtype counterparts and spun at 
1,000 x g for 10 minutes at 4˚C. The top layer, containing plasma, was obtained for analysis of TAG 
and NEFA content using a triglyceride colorimetric assay kit and free fatty acid fluorometric assay 
kit from Cayman chemicals (Ann Arbor, Mi), according to the manufacturer’s instructions.  
 
Statistical analysis  
Mice were divided into two groups based on Agpat4 expression (wildtype versus knockout). 
The results are shown as means ± SEM. Significance between the two groups was established using 
Student’s t-test (unpaired, two-tailed) and significance between multiple groups was established by 
one-way analysis of variance with Bonferroni’s post hoc test. Differences were considered significant 
at P < 0.05.  
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Chapter 5: Results 
	
Agpat4 is expressed in adipose tissue  
To confirm Agpat4 expression in perirenal WAT, and determine if expression is depot specific, RT-
PCR was utilized to visualize bands in an ethidium bromide gel (Fig. 5A) and quantified (Fig. 5B). 
Analysis indicated expression within each adipose tissue depot in C57Bl/6J mice without any 
statistically significant differences between the regions. 
                       
 
Figure 5. Agpat4 expression in multiple adipose tissue depots in C57Bl/6J mice. A, 
Representative ethidium bromide gel showing murine Agpat4 expression, as measured by RT-PCR, 
in various adipose depots, in C57Bl/6J mice. B, Quantification of AGPAT4 mRNA expression, as 
measured by RT-PCR, in various adipose depots. (n=3). Data are means ± SEM 
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Agpat4 gene ablation results in loss of Agpat4 expression in WAT  
To determine the critical biochemical and physiological role of AGPAT4 in adipose tissue, an 
Agpat4 gene ablation model was created. To confirm the absence of Agpat4 expression in the adipose 
tissues analyzed in this dissertation, RT-PCR was utilized. The absence of a band corresponding to 
Agpat4, relative to 18S expression, was confirmed in both epididymal (Fig. 6A) and perirenal (Fig. 
6B) white adipose tissue.  
	
	
 
Figure 6. Agpat4 expression in wildtype and Agpat4-/- mice. RT-PCR confirming the absence of 
Agpat4 expression in Agpat4-/- mice in A, epididymal WAT and B, perirenal WAT. (n=3).  
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Epididymal WAT weight is higher in Agpat4-/- mice but whole body weights are not different 
Whole body weights of Agpat4-/- and wildtype mice were recorded but no statistically significant 
differences were found (Fig. 7A). The weights of individual adipose tissue depots were also assessed 
and expressed as mg of tissue per g of body weight (Fig. 7B). No statistically significant differences 
were seen between Agpat4-/- and wildtype mice for the perirenal, retroperitoneal, or inguinal white 
adipose or the subscapular brown adipose depots. However, analysis indicated that the epididymal 
WAT depot in Agpat4-/- mice showed a 40% increase in weight compared to wildtype littermate 
controls (24.65 ± 2.00 versus 17.60 ± 1.46 mg tissue/g body weight, respectively, P < 0.05). 
 
 
Figure 7. Body mass and adipose depot weight analysis.  A, Mouse carcass mass as determined 
immediately after exsanguination at age 9-12 weeks (n=25-28). B, Adipose depot weights from 
wildtype and Agpat4-/- mice as expressed relative to whole body weight. (n=20-34). Data are means ± 
SEM. *P < 0.05 vs. wildtype.  
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Loss of Agpat4 does not alter food intake, activity, or energy metabolism 
To determine if the greater epididymal WAT weight in Agpat4-/- is due to differences in dietary 
consumption, activity, or energy metabolism, CLAMS was used to assess food intake, total activity, 
dual beam movement, Z-axis movement, RER, heat expended, fat oxidation, carbohydrate oxidation, 
daily average VO2, VO2 awake, and VO2 sleeping (Fig. 8). There were no significant differences 
measured during the 72 hour period, suggesting the difference in epididymal WAT weight is not due 
to differences in food intake, activity, or energy metabolism.  
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Figure 8. Measures of food intake, activity, and energy metabolism in Agpat4-/- and wildtype 
mice. Measures of whole body physiology, as determined through CLAMS. A, RER. B, heat 
expended. C, fat oxidation. D, carbohydrate oxidation. E, food intake. F, total activity. G, dual beam 
movement. H, Z-axis movement. I, daily average VO2. J, VO2 awake. K, VO2 sleeping. (n=14-15). 
Data are means ± SEM.  
	
TAG content is increased in the epididymal WAT of Agpat4-/- mice 
Total lipid extracts were obtained from Agpat4-/- mice and their wildtype counterparts from 
epididymal WAT, to determine if an increase in TAG is resulting in the increase in epididymal WAT 
weights in the Agpat4-/- mice. Total lipid extracts were also taken from a second visceral depot, the 
perirenal WAT depot, for comparison. The lipid extracts from both depots were subjected to TLC to 
separate TAG for GC analysis and the results are expressed as µg of fatty acid per mg of tissue. 
Epididymal WAT from Agpat4-/- mice had a 26% significantly greater TAG content compared to 
wildtype mice (936.26 ± 52.75 versus 741.02 ± 21.61 µg FA/mg adipose tissue, respectively, P < 
0.05) (Fig. 9A).This was accompanied by a significantly greater content of saturated fatty acids 
(SFA) in the TAG in Agpat4-/- mice (33% greater; 473.85 ± 32.91 versus 355.80 ± 30.99 µg SFA/mg 
epididymal adipose tissue, P < 0.05) (Fig. 9B) and a significantly greater content of monounsaturated 
fatty acid (MUFA) in the TAG in Agpat4-/- mice (392.06 ± 27.52 versus 321.14 ± 13.20 µg 
MUFA/mg epididymal adipose tissue, P < 0.05) (Fig. 9C). No significant differences were found 
between wildtype and knockout mice in the epididymal TAG n-6 (Fig. 9D) or n-3 (Fig. 9E) 
composition. In perirenal WAT, no significant differences in total TAG content or fatty acid 
composition were observed (Fig. 10). 
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Figure 9. Triacylglycerol and fatty acid analysis of epididymal WAT. GC analysis of the total 
lipid extract of epididymal WAT in Agpat4-/- and wildtype mice. A, TAG concentration. B, TAG SFA 
content. C, TAG MUFA content. D, TAG n-6 polyunsaturated fatty acids (PUFA). E, TAG n-3 
PUFA. (n=4). *P < 0.05 vs. wildtype.  
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Figure 10. Triacylglycerol and fatty acid analysis of perirenal WAT. GC analysis of the total 
lipid extract of perirenal WAT in Agpat4-/- and wildtype mice. A, TAG concentration. B, TAG SFA 
content. C, TAG MUFA content. D, TAG n-6 PUFA. E, TAG n-3 PUFA. (n=5). Data are ± SEM.  
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PA content is increased in the epididymal WAT of Agpat4-/- mice  
Previously, Bradley et al. (48) showed that the brains of Agpat4-/- mice have decreased PI, PE, and 
PC content. To determine if this decrease in specific phospholipids is tissue specific, or if the same 
changes are evident in adipose tissue as well, total lipid extracts of epididymal and perirenal WAT 
from Agpat4-/- and wildtype mice were subjected to polar lipid TLC separation, to resolve the 
individual classes of phospholipids, followed by GC analysis. The results are expressed as µg of fatty 
acid per g of tissue. Epididymal WAT from Agpat4-/- mice exhibited 74% greater total cellular PA 
content compared to wildtype mice (150.76 ± 25.97 versus 86.52 ± 8.71 µg FA/g adipose tissue, P < 
0.01) but no significant differences were observed in the content of PC, PE, PI, PG, PS, or CL (Fig. 
11A). In perirenal WAT, no significant differences were observed in the content of any of the 
measured phospholipids (Fig. 11B).  
 
 
 
Figure 11. Phospholipid content of epididymal and perirenal WAT. Phospholipid content, as 
determined by GC analysis, of the total lipid extract of A, Epididymal WAT and B, Perirenal WAT of 
Agpat4-/- and wildtype mice. (n=4-5). Data are ± SEM. *P < 0.05 vs. wildtype. 
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Lipid droplet size, but not differentiation, is increased in the epididymal WAT of Agpat-/- mice  
Increased WAT mass and subsequently, TAG content, can result from an increase in adipocyte 
number, due to increased adipogenesis, or from an increase in adipocyte size (77). To determine if 
the Agpat4-/- mice show increased adipogenesis in the epididymal WAT depot, expression was 
analyzed for genes encoding proteins involved in adipocyte differentiation using qPCR (Fig. 12A). 
The results were also compared to analysis of gene expression in the perirenal WAT depot (Fig. 
12B). No significant differences were found in the expression of genes encoding C/EBPα, C/EBPβ, 
PREF-1, PPARγ, iPLAβ, iPLAγ, aP2/FABP4, or FAT/CD36 between wildtype and Agpat4-/- mice in 
either the epididymal or the perirenal WAT depot, suggesting that the degree of differentiation of 
these depots did not differ significantly between wildtype and Agpat4-/- mice, and that an increase in 
adipocyte size was more likely to be responsible for the increase in epididymal WAT mass. 
 
Figure 12. Adipogenic gene expression. Analysis of expression of genes encoding enzymes 
involved in adipocyte differentiation in Agpat4-/- and wildtype mice from A, epididymal WAT and B, 
perirenal WAT. (n=5-7). Data are means ± SEM. 
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To assess if adipocyte size increased, in accordance with the increase in epididymal WAT weight and 
TAG content in Agpat4-/- mice, epididymal WAT was sectioned and stained with hematoxylin and 
eosin (Fig. 13), and five separate fields were counted from four different mice. The results were 
compared with that of perirenal WAT (Fig. 14). Histological analysis indicated a greater frequency 
of large adipocytes in epididymal WAT of Agpat4-/-mice when compared to wildtype littermates as 
seen by the presence of significantly more adipocytes >1300 µm2 in Agpat4-/- mice. The average 
adipocyte cell size was also significantly greater in Agpat4-/- mice. These differences were not see in 
perirenal WAT.  
 
Figure 13. Adipocyte size in epididymal WAT. A, Representative image of wildtype hematoxylin 
& eosin-stained sections of epididymal WAT and frequency distribution of adipocyte cell size. B, 
Representative image of Agpat4-/- hematoxylin & eosin-stained sections of epididymal WAT and 
frequency distribution of adipocyte cell size. C, Average adipocyte cell size. (n=4). Data are means ± 
SEM. ****P < 0.0001 vs. wildtype. 
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Figure 14. Adipocyte size in perirenal WAT. A, Representative image of wildtype hematoxylin & 
eosin-stained sections of perirenal WAT and frequency distribution of adipocyte cell size. B, 
Representative image of Agpat4-/- hematoxylin & eosin-stained sections of perirenal WAT and 
frequency distribution of adipocyte cell size. C, Average adipocyte cell size. (n=4). Data are means ± 
SEM.  
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Genes involved in TAG synthesis are upregulated in epididymal WAT of Agpat4-/- mice 
To assess if the increase in TAG content and adipocyte size in the epididymal WAT of Agpat4-/- mice 
is due to an increase in TAG synthesis, expression of a panel of genes encoding Kennedy pathway 
enzymes was assessed by qPCR on epididymal WAT cDNA from Agpat4-/- and wildtype mice (Fig. 
15A). Gene analysis using perirenal WAT was also performed (Fig. 15B). Results shown are 
expressed relative to 18S. In epididymal WAT from Agpat4-/- mice, expression of two lipid synthetic 
genes was elevated. Expression of the gene encoding LIPIN1 was significantly higher (2.3-fold) as 
well as expression of the gene encoding DGAT1 (2.0-fold). There were no significant differences in 
the expression of Dgat2, Cds1, Cds2, Cdipt, Pgs1, Cept1, or Chpt1.  No significant differences were 
seen for perirenal WAT in the expression of any of the genes encoding Kennedy pathway proteins.  
 
Figure 15. Kennedy pathway gene expression analysis. Analysis of expression of genes encoding 
enzymes involved in the Kennedy pathway in Agpat4-/- and wildtype mice from A, epididymal WAT 
and B, perirenal WAT. (n=5-7). Data are ± SEM. *P < 0.05 vs. wildtype.  
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Fatty acid synthesis enzymes are not altered in Agpat4-/- mice in epididymal or perirenal WAT  
To assess if the increase in TAG content or fatty acid composition is due to an increase in fatty acid 
metabolism in the Agpat4-/-mice, immunoblotting was utilized to measure the protein content of 
various enzymes involved in fatty acid metabolism in epididymal white adipose tissue (Fig. 16) and 
perirenal white adipose tissue (Fig. 17). The results are expressed relative to total protein content per 
lane. There were no significant differences found in the protein content of ACC, P-ACC S79, AMPK 
α, or FAS between Agpat4-/- and wildtype mice in either the epididymal or perirenal adipose depots.  
 
 
Figure 16. Levels of epididymal WAT enzymes involved in de novo fatty acid synthesis. Shown 
are A, Western blots and B, relative quantification, for ACC, P-ACC S79, AMPK α, and FAS from 
epididymal WAT in Agpat4-/- and wildtype mice. (n=7-9). Data are ± SEM. 
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Figure 17. Levels of perirenal WAT enzymes involved in de novo fatty acid synthesis. Shown are 
A, Western blots and B, relative quantification, for ACC, P-ACC S79, AMPK α, and FAS from 
perirenal WAT in Agpat4-/- and wildtype mice. (n=7-9). Data are ± SEM. 
 
Levels of enzymes involved in lipolysis are decreased in Agpat4-/- mice in epididymal WAT 
In order to examine if the increase in TAG content in the epididymal adipose tissue of Agpat4-/- mice 
is due to a decrease in lipolysis, immunoblotting was utilized to assess levels of a panel of enzymes 
involved in the lipolysis pathway in Agpat4-/- and wildtype mice (Fig. 18). Perirenal adipose tissue 
was also analyzed (Fig. 19). In epididymal adipose tissue from Agpat4-/- mice, there was a significant 
~50% decrease in ATGL content, a significant ~40% decrease in P-HSL S563 content, and a 
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significant ~60% decrease in P-HSL S660 content. No significant differences were observed in the 
content of HSL, P-HSL S565, or perilipin. The perirenal adipose tissue from Agpat4-/- mice showed 
no significant differences in the content of ATGL, HSL, P-HSL S563, P-HSL S565, P-HSL S660, or 
perilipin.  
 
 
Figure 18. Levels of epididymal WAT enzymes involved in lipolysis. Shown are A, Western blots 
and B, relative quantification, for ATGL, HSL, P-HSL S563, P-HSL S565, P-HSL S660 and perilipin 
from epididymal WAT in Agpat4-/- and wildtype mice. (n=7-9). Data are ± SEM. *P < 0.05 vs. 
wildtype.  
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Figure 19. Levels of perirenal WAT enzymes involved in lipolysis. Shown are A, Western blots 
and B, relative quantification, for ATGL. HSL. P-HSL S563, P-HSL S565, P-HSL S660 and perilipin 
from perirenal WAT in Agpat4-/- and wildtype mice. (n=7-9). Data are ± SEM. 
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Lipolysis is decreased in Agpat4-/- mice in epididymal WAT  
To determine if the decrease in protein content of enzymes involved in lipolysis corresponds to a 
decrease in lipolytic activity in the epididymal adipose depot of the Agpat4-/-mice, an in vitro 
radiochemical triolein hydrolase assay was utilized. The amount of total triolein lipase activity, as 
measured by the production of 3H-oleate, in Agpat4-/- and wildtype mice, was determined in extracts 
from epididymal adipose tissue (Fig. 20A) and compared to the perirenal adipose depot (Fig. 20B). 
The results are expressed as nmol [3H]oleic acid hydrolyzed/min/mg protein. A significant ~30% 
decrease in 3H-oleate was observed between the epididymal adipose tissue from Agpat4-/- mice and 
wildtype littermates (0.055 ± 0.0047 versus 0.039 ± 0.0055 nmol/min/mg protein) whereas no 
significant differences were seen for the perirenal adipose depot.  
 
 
Figure 20. Triacylglycerol lipase activity in Agpat4-/- and wildtype mice. The amount of total 
triolein lipase activity, as measured by the production of 3H-FA, in Agpat4-/- and wildtype mice. A, 
epididymal WAT. B, perirenal WAT. (n=6-7). Data are ± SEM. *P < 0.05 vs. wildtype. 
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To confirm the decrease in lipolysis in the epididymal WAT of Agpat4-/- mice, an in situ lipolysis 
assay was utilized in which glycerol and free fatty acid release was measured from epididymal tissue 
explants (Fig. 21). This was studied under both basal and dibutyryl-cAMP stimulated conditions. All 
findings are expressed as mg/ml, relative to basal release at time point 0 hours. In agreement with the 
findings from the in vitro triolein hydrolase assay, cAMP stimulated glycerol release was found to be 
significantly lower, by 16.9% at 2 hours (0.15 ± 0.043 versus 0.18 ± 0.0045 mg/ml glycerol released, 
P<0.05) and significantly lower by 13.5% at 4 hours (0.22 ± 0.0047 versus 0.25 ± 0.017 mg/ml 
glycerol released, P<0.01). Basal glycerol, basal NEFA, and cAMP-stimulated NEFA release from 
epididymal WAT explants, increased over time in both the Agpat4-/- and wildtype groups however, 
there were no statistically significant differences at any time point for these measures.  
 
Figure 21. Glycerol and NEFA release from epididymal WAT explants. From the in situ lipolysis 
assay, using epididymal WAT tissue explants from Agpat4-/- and wildtype mice, the amount of A, 
glycerol release under unstimulated (basal) conditions. B, NEFA release under unstimulated (basal) 
conditions. C, glycerol release under dibutyryl-cAMP stimulated conditions. D, NEFA release under 
dibutyryl-cAMP stimulated conditions. (n=4). Data are ± SEM. *P < 0.05 vs. wildtype. **P < 0.01 
vs. wildtype.  
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Plasma TAG and NEFA levels are unchanged in Agpat4-/- mice 
To determine if the observed decrease in lipolysis in the epididymal WAT of Agpat4-/- mice is 
associated with changes in blood, plasma NEFA and TAG concentrations were determined (Fig. 22). 
Results are expressed in mg/dL. No statistically significant differences were found between Agpat4-/- 
mice and their wildtype littermates for plasma NEFA or plasma TAG. 	
 
 
Figure 22. Plasma NEFA and TAG concentrations. Plasma concentration measurements in 
Agpat4-/- and wildtype mice for A, NEFA and B, TAG. (n=5). Data are ± SEM. 
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Other AGPAT isoforms are upregulated in perirenal WAT, but not epididymal WAT in Agpat4-/- mice 
To investigate the observed differences between Agpat4-/- and wildtype mice in the epididymal WAT 
depot, relative to the lack of differences found in the perirenal WAT depot, RT-PCR was utilized to 
analyze the expression of the other AGPAT isoforms. Expression of Agpat1, Agpat2, Agpat3, and 
Agpat5 was determined for both adipose tissue depots and results are expressed relative to 18S 
expression (Fig. 23). No significant upregulation of Agat1, Agpat2, Agpat3, or Agpat5 was found in the 
epididymal WAT of Agpat4-/- mice compared to their wildtype counterparts. In contrast, there was a 
significant 3.65-fold increase in the expression of Agpat1, a significant 3.36-fold increase in the 
expression of Agpat2, a significant 1.81-fold increase in the expression of Agpat3, and a significant 1.98-
fold increase in the expression of Agpat5 in the perirenal WAT of Agpat4-/- mice compared to their 
wildtype counterparts. 
 
Figure 23. Expression of other AGPAT isoforms. Representative RT-PCR agarose image and 
quantification for Agpat1, Agpat2, Agpat3, and Agpat5 in A, epididymal WAT and B, perirenal 
WAT. (n=4). Data are ± SEM. *P < 0.05 vs. control. **P < 0.01 vs. wildtype.  
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Chapter 6: Discussion 
	
The AGPAT family of enzymes contains five true AGPAT isoforms, each showing different 
tissue expression patterns and functional preferences (18). We have shown previously that AGPAT4 
is highly expressed in the brain (48, 64) and here we demonstrate that it is also abundant in various 
adipose depots including epididymal white adipose, perirenal white adipose, retroperitoneal white 
adipose, inguinal white adipose, and subscapular brown adipose tissue. (BAT). WAT is currently 
known to highly express AGPAT2 and AGPAT6, which both have been shown to play a significant 
role in determining TAG content. Therefore, we -investigated the role of AGPAT4 in white adipose 
tissue using a gene ablation model.  
Initially, we hypothesized that mice deficient for AGPAT4 would exhibit an impaired ability 
to produce TAG since the AGPAT family of enzymes function in the production of PA, the 
branching point for TAG and glycerophospholipid synthesis. We also hypothesized that this would 
result in decreased adipose tissue depot weights, as well as a decrease in whole body mass. 
Surprisingly, we found that loss of Agpat4 did not result in a change in whole body weights or a 
significant change in the weights of the perirenal, retroperitoneal, inguinal, or subscapular brown 
adipose depots, but a significant increase in the weight of the epididymal white adipose depot. This is 
in contrast to Agpat2-/- mice, which demonstrate a complete absence of both WAT and BAT, 
although these mice did not have a difference in body weights since TAG was stored ectopically in 
organs throughout the body, most notably, the liver (78). This is also in contrast to Agpat6-/- mice, 
which have adipose tissue, but exhibit reduced TAG contents in WAT, reduced adipocyte size in 
epididymal WAT, and a decrease in total body weights stemming from increased energy expenditure, 
resulting in resistance to diet-induced obesity (67).  
To explain the unanticipated phenotype of epididymal WAT in Agpat4-/- mice, we first 
investigated measures of whole body physiology, including food intake, activity, and energy 
metabolism, but failed to find any significant differences. This suggests that AGPAT4 does not play 
a critical role in determining RER, the ratio of carbon dioxide (VCO2) to oxygen consumption (VO2) 
which indicates which fuel source is being primarily metabolized. AGPAT4 was also shown to not 
play a critical role in determining the amount of heat expended, fat and carbohydrate oxidation, 
amount of food intake, total activity or dual beam and Z axis movement, as well as daily average 
VO2, VO2 awake, or VO2 sleeping. 
We next investigated the nature of the difference in epididymal WAT, and found that the 
larger depot size in Agpat4-deficient mice was associated with a greater content of total TAG, which 
47	
	
was predominantly acylated with saturated and monounsaturated fatty acids. In contrast, perirenal 
WAT depots, which did not differ in mass between wildtype and Agpat4-/- mice, exhibited no 
difference in TAG content or TAG fatty acyl composition. The observed increase in depot-specific 
TAG content may be attributed to a either a difference in adipocyte cell size, which is strongly 
suggested by the normalized increase in TAG content of epididymal WAT, or a difference in 
adipocyte differentiation (20, 77, 79).  
Loss of Agpat4 did not significantly alter the expression level of adipogenic marker genes 
including C/ebpα, C/ebpβ, Pref-1, Pparγ, iPlaβ, iPlaγ, Ap2/Fabp4, or Fat/Cd36, suggesting normal 
adipocyte differentiation in both the epididymal and perirenal WAT depots. This finding was 
somewhat unexpected, since we hypothesized that ablation of an AGPAT isoform would potentially 
result in a build-up of its substrate, LPA, which has been shown to have a key role in inhibition of 
adipogenesis (80). The lack of change in expression of key transcriptional activators of the 
adipogenic program in Agpat4-/- mice suggests that the role of AGPAT4 in determining TAG content 
is independent of alterations in adipocyte differentiation. In agreement, histological analysis revealed 
a greater frequency of larger adipocytes in the epididymal WAT of Agpat4-/- mice, and a statistically 
significant increase in average adipocyte size. This strongly suggests that larger epididymal depots in 
Agpat4-/- mice result from increases in adipocyte cell size rather than number. As expected, we did 
not observe a difference in adipocyte cell size frequency, or a change in average adipocyte size, in 
perirenal WAT. 
Lipogenesis and lipolysis are major biochemical functions of adipose tissue that regulate 
TAG content. Determination of changes in these processes may provide mechanistic insight into the 
observed increase in TAG in the epididymal WAT of Agpat4-/- mice. Expression level was measured 
for genes encoding Kennedy pathway proteins as well as the protein content of enzymes involved in 
fatty acid synthesis. No differences were found in epididymal WAT for the expression of Cds1, 
Cds2, Cdipt, Pgs1, Cept1, or Chpt1, which code for proteins involved in the formation of PI, PE, PC, 
PG, PS, and CL or for the content of ACC, P-ACC S79, AMPK α or FAS, which participate in the de 
novo synthesis of fatty acids. However, an upregulation was observed in the expression of Lipin1, the 
gene encoding the enzyme PAP, which catalyzes the formation of DAG from PA in a step that is 
critical for TAG synthesis (34). In addition, Dgat1 was upregulated, although Dgat2 was not. Both 
isoforms are highly expressed in WAT and are involved in the formation of TAG from DAG, but do 
not show sequence or protein homology, and have been shown to have distinct physiological roles 
through the generation of gene ablation models (36, 81-83). A mouse overexpression model of 
DGAT1, but not DGAT2, has been shown to increase liver VLDL secretion, resulting in increased 
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epididymal WAT weight (84). This was attributed to the high expression of the VLDL receptor in the 
epididymal fat pad causing a VLDL-mediated increase in epididymal WAT mass (84). These 
findings suggest that the increased Dgat1 expression in the epididymal WAT depot in Agpat4-/- mice 
may be contributing to the increase in total cellular TAG content either directly, through the 
conversion of DAG to TAG, or indirectly, through an increase in the uptake of VLDL. Together, 
these results indicate that Agpat4 ablation has little effect on phospholipid synthesizing enzymes or 
on early steps in TAG synthesis including de novo lipogenesis, but does appear to promote enzymatic 
steps in formation of TAG, specifically. No differences were found in the perirenal WAT depot with 
regards to the expression of any Kennedy pathway marker genes or enzymes involved in fatty acid 
synthesis.  
We also explored whether changes in TAG lipolysis could help explain the increase in 
epididymal WAT weight, adipocyte size, and TAG content. A decrease in HSL phosphorylated at the 
serine 563 and 660 sites, as well as total ATGL, was observed in the epididymal WAT of Agpat4-/-, 
while no differences were observed in the amounts of total HSL, HSL phosphorylated at the S565 
site, or perilipin. The increase in protein content of lipolytic enzymes was accompanied by a 30% 
increase in total triolein hydrolase activity. No differences were observed in lipolytic proteins or 
triolein lipase activity in perirenal WAT. Adipocyte lipolysis is activated during times of energy 
deprivation. This increases hydrolytic activity of ATGL, which cleaves a fatty acyl chain from the 
sn-2 position of TAG forming DAG, and HSL, which subsequently cleaves a fatty acyl chain from 
the sn-1 or sn-3 positions of DAG to produce MAG (20). During lipolysis stimulation, intracellular 
cAMP levels increase, activating cAMP-dependent PKA to phosphorylate HSL at the serine residues 
563 and 660, causing translocation of the enzyme to the lipid droplet (21). These findings therefore, 
suggest a decrease in cAMP-stimulated lipolytic activity in the epididymal WAT of Agpat4-/- mice. 
In situ analysis supported this contention, since there were no significant differences between 
wildtype and Agpat4-/- littermates when glycerol and NEFA release were assessed under basal 
conditions, but there was a significant reduction in glycerol release from epididymal WAT explants 
stimulated with dibutyryl cAMP. Interestingly, there were no corresponding significant differences in 
NEFA release from epididymal WAT explants under stimulated conditions. Glycerol is produced 
when lipolysis proceeds to completion, and is exported from adipocytes that lack glycerol kinase 
activity and therefore cannot reutilize this structure in lipid synthesis. NEFA, however, can be used 
directly in adipocytes, either for re-esterification into complex lipids, or for beta-oxidation and 
energy provision. No significant differences were found in plasma TAG and NEFA levels, further 
suggesting increased re-esterification of released NEFA in adipose tissue of Agpat4-/- epididymal 
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WAT. Further study however, will be required to determine the major metabolic fate(s) of lipolysis-
derived fatty acids from Agpat4-/- epididymal WAT.   
In perirenal WAT, PA levels were not significantly different between wildtype and Agpat4-/- 
mice. As was observed previously in brain, a compensatory upregulation of other AGPAT isoforms 
may aid in explaining this (48). In perirenal WAT, loss of Agpat4 resulted in increased gene 
expression of the other true AGPAT/LPAAT isoforms, Agpat1, Agpat2, Agpat3, and Agpat5. 
Importantly, this appears to have both normalized PA content, and preserved biochemical and 
physiological functioning of this WAT depot, since no differences in TAG or other PL species were 
observed, and no differences in lipolysis, lipogenesis, or apparent differentiation were detected. This 
finding is in contrast to our previous observations in brain, where loss of Agpat4 did not reduce total 
PA level, but did reduce levels of PC, PE, and PI (48).  
In contrast, PA levels were significantly elevated in epididymal WAT from Agpat4-/- mice 
compared to wildtype littermates, and yet we observed no difference in expression of the other Agpat 
isoforms in this depot. It has been shown that AGPAT isoforms 1, 3, and 5 are significantly 
upregulated in the livers of male Agpat2-/-  mice (78), but are downregulated in Agpat2 knockdown 
OP9 cells (69). Taken together with findings from the current study, this indicates that the 
coordinated response of different AGPAT isoforms is not only tissue-specific, but also depot-specific 
with regards to adipose tissue. This finding has particular importance for adipose tissue biology 
research, since it indicates a startling heterogeneity in the molecular physiology of closely positioned 
depots that are often considered as a single entity (i.e. “visceral adipose tissue”).  
When considered relative to findings in perirenal WAT, it seems highly likely that the absence of a 
compensatory upregulation of the other AGPAT isoforms, and the paradoxical elevation in 
epididymal WAT PA levels, are causal in generating the marked changes observed specifically in 
this depot. PA is a precursor for TAG synthesis, and while the source of increased epididymal PA 
content remains undetermined, upregulated Lipin1 and Dgat1 expression suggest it is likely utilized 
to increase TAG production. PA is also involved in the biophysical processes underlying lipid droplet 
formation and lipid droplet TAG accretion, and therefore may directly promote the enhanced storage 
of lipid in this tissue (85, 86). For example, in brown adipose tissue, lipid droplets have been shown 
to enlarge through the docking of two lipid droplets and subsequently, the transference of lipids 
between the pairs. This process is facilitated by the amphipathic helix of CIDEA, a protein that 
interacts with PA on the lipid droplet phospholipid monolayer to increase phospholipid barrier 
permeability (85). In addition, PA is an allosteric activator of phosphodiesterase 4, which hydrolyzes 
cAMP to decrease activation of PKA (87, 88). It is therefore, highly plausible that decreased 
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stimulated lipolysis in epididymal WAT from Agpat4-/- mice resulted, at least in part, from elevated 
tissue levels of PA. With regards to differentiation, PA has been found to block the differentiation of 
cultured 3T3-L1 adipocytes, but overexpression of Lipin1 can rescue this (89). In epididymal WAT 
from Agpat4-/- mice, elevated PA content was observed together with an upregulation of Lipin1, and 
therefore these two effects may have prevented any adverse effects on adipocyte differentiation.  
In summary, we have characterized two closely positioned visceral WAT depots from 
Agpat4-/- mice and their wildtype littermates. Although perirenal and epididymal WAT express 
similar levels of Agpat4, we have found differences between these two depots in the biochemistry, 
molecular physiology, functional processes, and compensatory responses, as a result of loss of this 
isoform. In perirenal WAT, an induction of the other Agpat/Lpaat isoforms (1, 2, 3, and 5) resulted in 
an essentially perfect compensation with regards to restoration of cellular PA levels, as well as 
maintenance of all cellular processes in a state that was indistinguishable from wildtype. In 
epididymal WAT however, there was no compensatory induction of the other Agpat/Lpaats, and 
metabolic perturbations were evident in most biochemical and physiological processes examined. 
This work therefore provides novel information on the differential role of Agpat4 in perirenal and 
epididymal WAT, highlighting important differences between these two depots.  
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Chapter 7: Study limitations and future directions  
 
Limitations 
	 The foremost limitation in this study of characterizing the critical role of AGPAT4 in white 
adipose tissue is the use of a global Agpat4-/- mouse model. Although the model aids in examining the 
effect of total loss of AGPAT4, it fails to elucidate the white adipose tissue specific effects that it 
plays. The findings in this study may, in part, be explained by other changes in the global Agpat4-/- 
model that are contributing to the differences within the epididymal WAT depot. Immortalized 
depot-specific adipocyte cell lines would aid in elucidating the intrinsic biochemical differences 
between different visceral adipose depots as well as the role AGPAT4 plays in determining their 
physiology. Future work will aim to address these limitations.  
Future Directions 
Future studies will investigate the biological significance and consequences of our findings 
that increased TAG content and decreased lipolysis accompanies loss of Agpat4 in the epididymal 
WAT depot. Of particular interest are the downstream effects on spermatogenesis and reproduction, 
since epididymal WAT is necessary for these processes (90). In male Syrian hamsters, the complete 
absence of epididymal WAT eliminated spermatogenesis, decreased seminiferous tubule size, and 
resulted in aspermatic ejaculate, with no changes in testosterone levels or behaviour (90). In the 
present study using Agpat4 ablated mice, weights of testicular tissue were not altered, and 
reproduction was not prevented, although male to female sex ratios were altered (data not shown). 
Further examination of the differences between individual visceral WAT depots is also of interest. 
There are known disparities between visceral and subcutaneous WAT, such as developmental origin, 
metabolic activity, mitochondrial content, rate of lipolysis, and correlation to insulin resistance and 
other metabolic diseases (4, 11, 12, 91, 92). However, the present study suggests significant 
metabolic differences between individual visceral WAT depots. Further work will be needed to 
address the role of Agpat4 in the formation of TAG in these depots, as well as the role of other 
Agpats in regulation of depot-specific characteristics.  
Our studies with Agpat4-deficient mice demonstrate that AGPAT4 plays a non-redundant 
role in different visceral WAT depots, as well as in brain (48). The present study revealed new 
insight into the function of AGPAT4 in TAG accumulation and synthesis, as well as lipolysis, and 
underscores the complexity of the roles of the different AGPAT isoforms, as well as the complex 
regulation of different visceral WAT depots. Future studies will aim to delineate the mechanisms by 
which AGPAT4 mediates effects observed in epididymal WAT. 
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Appendix 
	
Table 3. TAG fatty acid composition in epididymal WAT and perirenal WAT  
	 Wildtype 
Epididymal WAT 
Agpat4-/- 
Epididymal WAT 
Wildtype 
Perirenal WAT 
Agpat4-/- 
Perirenal WAT 
C 14:0 4.61 10.52 4.30 4.52 
C 16:0 121.02 221.87 94.95 92.08 
C 17:0 1.23 1.65 0.94 0.75 
C 18:0 11.80 18.10 13.33 10.09 
C 20:0 0.49 0.76 0.60 0.52 
C 22:0 0.67 0.72 0.32 0.27 
C 24:0 1.86 2.89 0.31 0.36 
Total SFA 141.68 256.50* 114.75 108.59 
     
C 16:1 6.00 13.50 9.92 13.52 
C 18:1n-7 2.85 5.49 6.08 5.45 
C 18:1n-9 36.13 63.11 82.49 73.33 
C 20:1n-9 5.25 11.36 4.07 2.10 
C 22:1n-9 0.69 1.02 0.35 0.34 
C 24:1n-9 1.04 2.20 0.31 0.28 
Total MUFA 51.96 96.69* 103.21 95.01 
     
C 18:2n-6 0.77 1.41 12.32 7.49 
C 18:3n-6 0.06 0.06 0.01 0.02 
C 20:2n-6 0.22 0.29 0.07 0.06 
C 20:3n-6 0.09 0.10 0.01 0.02 
C 20:4n-6 0.08 0.10 0.02 0.02 
C 22:2n-6 0.06 0.05 0.01 0.02 
C 22:4n-6 1.37 0.41 0.28 0.12 
C 22:5n-6 0.19 0.20 0.05 0.13 
Total N-6  2.83 2.26 12.78 7.87 
     
C18:3n-3 0.50 0.56 0.49 0.21 
C20:3n-3 0.19 0.28 0.03 0.04 
C20:5n-3 0.22 0.25 0.34 0.20 
C22:6n-3 3.12 5.09 0.67 0.70 
Total N-3 4.02 6.17 1.52 1.15 
     
PUFAs 6.85 8.80 14.30 9.02 
HUFAs 5.25 6.42 1.40 1.23 
EPA+DHA 3.34 5.34 1.01 0.90 
N-6/N-3 0.77 0.42 9.06 6.98 
%n-3 HUFA 68.01 87.33 77.50 76.46 
     
Total 200.49 361.99* 232.26 212.61 
 
